Compared with mucinous glycoprotein vaccines, epidermal growth factor vaccines or ganglioside vaccines that modify only one tumor‐associated antigen, Tedopi vaccine led a significantly longer survival,[9] indicating that it is important to construct vaccines with a broad antigen spectrum for anti‐tumor immunity. This evidence concerns the gene EGF and neoplasm.